CASI - Juventas initiates registration study for CNCT19

CASI Pharmaceuticals' (CASI) partner Juventas has completed $65M financing and has initiated and enrolled the first patient in a Phase II registration study for CNCT19 (CD19 CAR-T) in China in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Juventas expects to start the Phase II study by year end. The financing provides with resources to continue moving CNCT19 through registration.Juventas is responsible for the development of CNCT19 while CASI and Juventas will co-commercialize the candiadate.

For further details see:

Juventas initiates registration study for CNCT19